[Special Stock] DXVX Hits Upper Limit on News of Accelerated Obesity Treatment Development↑
Biohealthcare specialist company DXVX has hit the upper price limit (the highest daily price limit).
As of 2:42 PM on the 18th, DXVX is trading at 2,195 KRW, up 506 KRW (29.96%) from the previous trading day.
This rise appears to be driven by news accelerating the development of an oral obesity treatment.
Hot Picks Today
!["Stock Surges from 255,000 Won to Over 2.2 Million"... Up 773% Yet Set to Climb Higher [This Week's Hot Stock]](https://cwcontent.asiae.co.kr/asiaresize/93/2026042810243143173_1777339471.jpg)
"Stock Surges from 255,000 Won to Over 2.2 Million"... Up 773% Yet Set to Climb Higher [This Week's Hot Stock]
- Despite a 10% Plunge, Target Price Raised from 2.5 Million to 4.2 Million Won... Why SK hynix's Target Price Was Increased [Click e-Stock]
- "Amputation with Scissors, Hard to Believe...But a Complicated Situation" — Practicing Doctor Weighs In on Incheon Nursing Hospital Controversy
- Buffett's Disciple Pabrai: "Never Sell Samsung or SK hynix"
- Was It Really Drugs? Shocking Turn as Suwon "Fentanyl Suspect" Tests Negative in Forensic Report: "I Was Just Weak"
On the same day, DXVX announced that based on previous research results confirming superiority over control substances in late-stage clinical trials, it is currently optimizing its oral GLP (glucagon-like peptide)-1 obesity drug candidate.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
